CL2011000109A1 - Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso. - Google Patents
Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso.Info
- Publication number
- CL2011000109A1 CL2011000109A1 CL2011000109A CL2011000109A CL2011000109A1 CL 2011000109 A1 CL2011000109 A1 CL 2011000109A1 CL 2011000109 A CL2011000109 A CL 2011000109A CL 2011000109 A CL2011000109 A CL 2011000109A CL 2011000109 A1 CL2011000109 A1 CL 2011000109A1
- Authority
- CL
- Chile
- Prior art keywords
- hyperexitability
- retigabine
- fluorobenzylamino
- disorder
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Formulación farmacéutica que comprende 30-70% de etil ester del ácido n-(2-amino-4-(fluorobencilamino)-fenil)carbámico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo aniónico y un polímero entérico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8216208P | 2008-07-18 | 2008-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000109A1 true CL2011000109A1 (es) | 2011-11-25 |
Family
ID=41550741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000109A CL2011000109A1 (es) | 2008-07-18 | 2011-01-18 | Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100120906A1 (es) |
EP (1) | EP2318001A4 (es) |
JP (1) | JP2011528666A (es) |
KR (1) | KR20110052641A (es) |
CN (1) | CN102170879B (es) |
AU (1) | AU2009270768A1 (es) |
BR (1) | BRPI0916000A2 (es) |
CA (1) | CA2731008A1 (es) |
CL (1) | CL2011000109A1 (es) |
CO (1) | CO6351716A2 (es) |
EA (1) | EA201170230A1 (es) |
IL (1) | IL210683A0 (es) |
MX (1) | MX2011000636A (es) |
NZ (1) | NZ590885A (es) |
WO (1) | WO2010009433A1 (es) |
ZA (1) | ZA201102518B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009013613A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
DE102009013612A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung |
WO2011055385A1 (en) * | 2009-11-03 | 2011-05-12 | Lupin Limited | Modified release formulation of lacosamide |
EA201290663A1 (ru) * | 2010-01-20 | 2013-03-29 | Вэлиант Фармасьютикалс Интернешнл | Состав с модифицированным высвобождением и способы применения |
EP2525788A2 (en) | 2010-01-20 | 2012-11-28 | Glaxo Group Limited | Novel retigabine composition |
WO2012098075A1 (en) | 2011-01-18 | 2012-07-26 | Glaxo Group Limited | Process for the preparation of retigabine |
AU2016328150B2 (en) | 2015-09-23 | 2020-10-01 | Xw Laboratories Inc. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
EP4069201A1 (en) * | 2019-12-02 | 2022-10-12 | Xenon Pharmaceuticals Inc. | Pediatric immediate-release formulation of the potassium channel opener ezogabine |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
DE4200259A1 (de) * | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
DE19701694A1 (de) * | 1997-01-20 | 1998-07-23 | Asta Medica Ag | Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung |
JP2000086509A (ja) * | 1998-09-14 | 2000-03-28 | Taisho Yakuhin Kogyo Kk | ソファルコン含有製剤の製造方法 |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
JP2003506388A (ja) * | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
US6117900A (en) * | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
WO2001066081A2 (de) * | 2000-03-08 | 2001-09-13 | Awd.Pharma Gmbh & Co.Kg | Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung |
US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
AU2002222567B2 (en) * | 2000-12-01 | 2007-05-10 | Kyowa Hakko Kirin Co., Ltd. | Composition improved in solubility or oral absorbability |
US6589986B2 (en) * | 2000-12-20 | 2003-07-08 | Wyeth | Methods of treating anxiety disorders |
AU2002338333A1 (en) * | 2001-04-04 | 2002-10-21 | Wyeth | Methods for treating hyperactive gastric motility |
AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
KR100425226B1 (ko) * | 2001-07-03 | 2004-03-30 | 주식회사 팜트리 | 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법 |
GB0120835D0 (en) * | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
SE0103369D0 (sv) * | 2001-10-09 | 2001-10-09 | Astrazeneca Ab | Pharmaceutical formulation |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
ES2323268T3 (es) * | 2002-07-29 | 2009-07-10 | Glaxo Group Ltd | Formulaciones de liberacion prolongada que contienen lamotrigina. |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
DE60324609D1 (de) * | 2002-09-17 | 2008-12-18 | Wyeth Corp | GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779 |
JP2004131393A (ja) * | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
ES2222831B2 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
NZ546183A (en) * | 2003-09-26 | 2011-04-29 | Alza Corp | Controlled release formulations exhibiting an ascending rate of release |
GB0324574D0 (en) * | 2003-10-21 | 2003-11-26 | Glaxo Group Ltd | Novel compositions |
US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
WO2006044202A2 (en) * | 2004-10-19 | 2006-04-27 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
EP1904039A2 (en) * | 2005-06-20 | 2008-04-02 | Cadila Healthcare Ltd. | Controlled release dosage formulation of duloxetine |
JP5543110B2 (ja) * | 2006-01-05 | 2014-07-09 | エッセンシャリス,インク. | カリウムatpチャネルオープナの塩およびその使用 |
US8558470B2 (en) * | 2006-01-20 | 2013-10-15 | Point Somee Limited Liability Company | Adaptive current regulation for solid state lighting |
USD601689S1 (en) * | 2006-05-12 | 2009-10-06 | Glaxo Group Limited | Pharmaceutical tablet |
BRPI0719590A2 (pt) * | 2006-11-28 | 2014-01-21 | Valeant Pharmaceuticals Int | Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio |
-
2009
- 2009-07-17 CA CA2731008A patent/CA2731008A1/en not_active Abandoned
- 2009-07-17 EA EA201170230A patent/EA201170230A1/ru unknown
- 2009-07-17 AU AU2009270768A patent/AU2009270768A1/en not_active Abandoned
- 2009-07-17 KR KR1020117003868A patent/KR20110052641A/ko not_active Application Discontinuation
- 2009-07-17 CN CN200980136417.8A patent/CN102170879B/zh not_active Expired - Fee Related
- 2009-07-17 EP EP09798829A patent/EP2318001A4/en not_active Withdrawn
- 2009-07-17 US US12/505,409 patent/US20100120906A1/en not_active Abandoned
- 2009-07-17 MX MX2011000636A patent/MX2011000636A/es not_active Application Discontinuation
- 2009-07-17 NZ NZ590885A patent/NZ590885A/xx not_active IP Right Cessation
- 2009-07-17 JP JP2011518947A patent/JP2011528666A/ja active Pending
- 2009-07-17 WO PCT/US2009/051052 patent/WO2010009433A1/en active Application Filing
- 2009-07-17 BR BRPI0916000A patent/BRPI0916000A2/pt not_active IP Right Cessation
-
2011
- 2011-01-16 IL IL210683A patent/IL210683A0/en unknown
- 2011-01-18 CL CL2011000109A patent/CL2011000109A1/es unknown
- 2011-02-17 CO CO11018953A patent/CO6351716A2/es not_active Application Discontinuation
- 2011-04-05 ZA ZA2011/02518A patent/ZA201102518B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201102518B (en) | 2012-06-27 |
EP2318001A1 (en) | 2011-05-11 |
MX2011000636A (es) | 2011-08-03 |
CO6351716A2 (es) | 2011-12-20 |
CN102170879A (zh) | 2011-08-31 |
JP2011528666A (ja) | 2011-11-24 |
BRPI0916000A2 (pt) | 2019-09-24 |
EA201170230A1 (ru) | 2011-08-30 |
CN102170879B (zh) | 2014-03-05 |
NZ590885A (en) | 2013-01-25 |
CA2731008A1 (en) | 2010-01-21 |
US20100120906A1 (en) | 2010-05-13 |
AU2009270768A1 (en) | 2010-01-21 |
KR20110052641A (ko) | 2011-05-18 |
WO2010009433A1 (en) | 2010-01-21 |
EP2318001A4 (en) | 2013-02-20 |
IL210683A0 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000109A1 (es) | Formulacion farmaceutica que comprende 30-70% de etilester del acido n-(2-amino-4-(fluorobencilamino)-fenil)carbamico (retigabina), 5-30% de una matriz que comprende hidroxipropilmetilcelulosa, 1,0-10% de un tensoactivo anionico y un polimero enterico; y su uso para tratar un trastorno de hiperexitabilidad del sistema nervioso. | |
ES2653207T3 (es) | Preparación líquida para protección biológica de plantas, procedimiento para su producción y uso de la misma | |
ES2525918T3 (es) | Proceso para la fabricación de Nicorandil | |
AR118273A2 (es) | Excipiente estabilizante para una vacuna de virus completo inactivado | |
CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
CL2011002827A1 (es) | Formulacion antiespumante que comprende un polimero de acrilato con un monomero de acido acrilico o acido metacrilico, un portador organico, un aditivo y un surfactante; su metodo de preparacion; y metodo para reducir o prevenir la generacion de espuma. | |
CL2008002998A1 (es) | Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion. | |
CL2008000063A1 (es) | Microcapsula que comprende una aglomeracion de microcapsulas primarias y una sustancia de carga; proceso de preparacion; y su uso para entregar una sustancia de carga a un sujeto. | |
CL2007003491A1 (es) | Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica. | |
CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
CR11648A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas | |
CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
CL2007000361A1 (es) | Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc. | |
CL2011002964A1 (es) | Composicion para controlar enfermedades de plantas que comprende acido 4-oxo-4-[(2-feniletilamino]-butirico y un inhibidor ajeno a quinona; agente de tratamiento de semillas; y uso. | |
RS52607B (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING VALSARTAN | |
EA201200728A1 (ru) | Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат | |
CL2008002537A1 (es) | Compuestos derivados de acido 6-fenil-nicotinico, con actividad moduladora de ppar-alfa; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar y/o prevenir dislipidemias, arteriosclerosis e insuficiencia cardiaca. | |
BR112021014944A2 (pt) | Toxinas apxia, apxiia e apxiiia inativas | |
CL2008001810A1 (es) | Compuestos derivados de espiroindolinas, moduladores de receptores de quimiocinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar aterosclerosis, dolor inflamatorio, influenza, sindrome metabolico, entre otras enfermedades. | |
CO6470857A2 (es) | Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos | |
BR112016022247A2 (pt) | Síntese eficaz de aminas e amidas a partir de álcoois e aldeídos com o uso de catálise em cascata | |
ECSP15022442A (es) | Producto de comicronización que comprende acetato de ulipristal | |
CL2007002862A1 (es) | Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha. | |
BR112022022431A2 (pt) | Composição amaciante sólida de tecido, tablete amaciante de tecido, método de produção de um tablete amaciante de tecido, método de amaciamento de roupas e uso de uma composição amaciante sólida de tecido | |
CY1120016T1 (el) | Φαρμακοτεχνικες μορφες οξικης κασποφουνγκινης |